| Report Title | Price | Action |
|---|---|---|
| Isocitrate Dehydrogenase [NADP] Mitochondrial (NADP(+)-Specific ICDH or Oxalosuccinate Decarboxylase or ICD M or IDP or IDH2 or EC 1.1.1.42) - Drugs in Development, 2021
Isocitrate Dehydrogenase [NADP] Mitochondrial (NADP(+)-Specific ICDH or Oxalosuccinate Decarboxylase or ICD M or IDP or IDH2 or EC 1.1.1.42) - Drugs i...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Short Transient Receptor Potential Channel 5 (Transient Receptor Protein 5 or TRPC5) - Drugs in Development, 2021
Short Transient Receptor Potential Channel 5 (Transient Receptor Protein 5 or TRPC5) - Drugs in Development, 2021 Summary Short Transient Receptor P...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Peripheral Nerve Injury (Central Nervous System) - Drugs in Development, 2021
Peripheral Nerve Injury (Central Nervous System) - Drugs in Development, 2021 Summary Peripheral Nerve Injury (Central Nervous System) - Drugs in De...
Published: Apr-2021 | No. of Pages: 40
|
$ 2000 | |
| Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021
Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021 Summary Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Develo...
Published: Apr-2021 | No. of Pages: 180
|
$ 2500 | |
| Lupus Nephritis (Immunology) - Drugs in Development, 2021
Lupus Nephritis (Immunology) - Drugs in Development, 2021 Summary Lupus Nephritis (Immunology) - Drugs in Development, 2021 provides an overview of ...
Published: Apr-2021 | No. of Pages: 90
|
$ 2000 | |
| Matrix Metalloproteinase (MMP or EC 3.4.24.) - Drugs in Development, 2021
Matrix Metalloproteinase (MMP or EC 3.4.24.) - Drugs in Development, 2021 Summary Matrix Metalloproteinase (MMP or EC 3.4.24.) - Drugs in Developmen...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.9 or SCN11A) - Drugs in Development, 2021
Sodium Channel Protein Type 11 Subunit Alpha (Peripheral Nerve Sodium Channel 5 or Sodium Channel Protein Type XI Subunit Alpha or Voltage Gated Sodiu...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Autoimmune Hepatitis (Gastrointestinal) - Drugs in Development, 2021
Autoimmune Hepatitis (Gastrointestinal) - Drugs in Development, 2021 Summary Autoimmune Hepatitis (Gastrointestinal) - Drugs in Development, 2021 pr...
Published: Apr-2021 | No. of Pages: 40
|
$ 2000 | |
| Status Epilepticus (Central Nervous System) - Drugs in Development, 2021
Status Epilepticus (Central Nervous System) - Drugs in Development, 2021 Summary Status Epilepticus (Central Nervous System) - Drugs in Development,...
Published: Apr-2021 | No. of Pages: 35
|
$ 2000 | |
| Lymphangioleiomyomatosis (Respiratory) - Drugs in Development, 2021
Lymphangioleiomyomatosis (Respiratory) - Drugs in Development, 2021 Summary Lymphangioleiomyomatosis (Respiratory) - Drugs in Development, 2021 prov...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Methyl CpG Binding Protein 2 (MECP2) - Drugs in Development, 2021
Methyl CpG Binding Protein 2 (MECP2) - Drugs in Development, 2021 Summary Methyl CpG Binding Protein 2 (MECP2) - Drugs in Development, 2021 provides...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) - Drugs in Development, 2021
Synaptic Functional Regulator FMR1 (Fragile X Mental Retardation Protein 1 or FMRP or FMR1) - Drugs in Development, 2021 Summary Synaptic Functional...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Chronic Liver Disease (Gastrointestinal) - Drugs in Development, 2021
Chronic Liver Disease (Gastrointestinal) - Drugs in Development, 2021 Summary Chronic Liver Disease (Gastrointestinal) - Drugs in Development, 2021 ...
Published: Apr-2021 | No. of Pages: 40
|
$ 2000 | |
| Substance (Drug) Abuse (Central Nervous System) - Drugs in Development, 2021
Substance (Drug) Abuse (Central Nervous System) - Drugs in Development, 2021 Summary Substance (Drug) Abuse (Central Nervous System) - Drugs in Deve...
Published: Apr-2021 | No. of Pages: 80
|
$ 2000 | |
| Lysosomal Storage Disorder (Metabolic Disorders) - Drugs in Development, 2021
Lysosomal Storage Disorder (Metabolic Disorders) - Drugs in Development, 2021 Summary Lysosomal Storage Disorder (Metabolic Disorders) - Drugs in De...
Published: Apr-2021 | No. of Pages: 60
|
$ 2000 | |
| Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) - Drugs in Development, 2021
Mineralocorticoid Receptor (Nuclear Receptor Subfamily 3 Group C Member 2 or Mineralocorticoid Receptor Delta or Aldosterone Receptor or MR or NR3C2) ...
Published: Apr-2021 | No. of Pages: 35
|
$ 3000 | |
| Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) - Drugs in Development, 2021
Thioredoxin (Trx or ATL Derived Factor or Surface Associated Sulphydryl Protein or TXN) - Drugs in Development, 2021 Summary Thioredoxin (Trx or ATL...
Published: Apr-2021 | No. of Pages: 30
|
$ 3000 | |
| Gaucher Disease Type I (Genetic Disorders) - Drugs in Development, 2021
Gaucher Disease Type I (Genetic Disorders) - Drugs in Development, 2021 Summary Gaucher Disease Type I (Genetic Disorders) - Drugs in Development, 2...
Published: Apr-2021 | No. of Pages: 40
|
$ 2000 | |
| Systemic Idiopathic Juvenile Arthritis (Musculoskeletal) - Drugs in Development, 2021
Systemic Idiopathic Juvenile Arthritis (Musculoskeletal) - Drugs in Development, 2021 Summary Systemic Idiopathic Juvenile Arthritis (Musculoskeleta...
Published: Apr-2021 | No. of Pages: 30
|
$ 2000 | |
| Major Depressive Disorder (Central Nervous System) - Drugs in Development, 2021
Major Depressive Disorder (Central Nervous System) - Drugs in Development, 2021 Summary Major Depressive Disorder (Central Nervous System) - Drugs i...
Published: Apr-2021 | No. of Pages: 170
|
$ 2000 |